ewcl1or

Property	Value
?:abstract	We are living through an unprecedented crisis with the rapid spread of the new coronavirus disease (COVID-19) worldwide within a short time The timely availability of thousands of SARS-CoV-2 genomes has enabled the scientific community to study the origin, structures, and pathogenesis of the virus The pandemic has spurred research publication and resulted in an unprecedented number of therapeutic proposals Because the development of new drugs is time consuming, several strategies, including drug repurposing and repositioning, are being tested to treat patients with COVID-19 Researchers have developed several potential vaccine candidates that have shown promise in phase II and III trials As of 12 November 2020, 164 candidate vaccines are in preclinical evaluation, and 48 vaccines are in clinical evaluation, of which four have cleared phase III trials (Pfizer/BioNTech\'s BNT162b2, Moderna\'s mRNA-1273, University of Oxford & AstraZeneca\'s AZD1222, and Gamaleya\'s Sputnik V vaccine) Despite the acquisition of a vast body of scientific information, treatment depends only on the clinical management of the disease through supportive care At the pandemic\'s 1-year mark, we summarize current information on SARS-CoV-2 origin and biology, and advances in the development of therapeutics The updated information presented here provides a comprehensive report on the scientific progress made in the past year in understanding of SARS-CoV-2 biology and therapeutics We are living through an unprecedented crisis with the rapid spread of the new coronavirus disease (COVID-19) worldwide within a short time. The timely availability of thousands of SARS-CoV-2 genomes has enabled the scientific community to study the origin, structures, and pathogenesis of the virus. The pandemic has spurred research publication and resulted in an unprecedented number of therapeutic proposals. Because the development of new drugs is time consuming, several strategies, including drug repurposing and repositioning, are being tested to treat patients with COVID-19. Researchers have developed several potential vaccine candidates that have shown promise in phase II and III trials. As of 12 November 2020, 164 candidate vaccines are in preclinical evaluation, and 48 vaccines are in clinical evaluation, of which four have cleared phase III trials (Pfizer/BioNTech\'s BNT162b2, Moderna\'s mRNA-1273, University of Oxford & AstraZeneca\'s AZD1222, and Gamaleya\'s Sputnik V vaccine). Despite the acquisition of a vast body of scientific information, treatment depends only on the clinical management of the disease through supportive care. At the pandemic\'s 1-year mark, we summarize current information on SARS-CoV-2 origin and biology, and advances in the development of therapeutics. The updated information presented here provides a comprehensive report on the scientific progress made in the past year in understanding of SARS-CoV-2 biology and therapeutics.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/3ewcl1or_hasAnnotation_C0017428> <https://research.tib.eu/covid-19/entity/3ewcl1or_hasAnnotation_C0042776> <https://research.tib.eu/covid-19/entity/3ewcl1or_hasAnnotation_C1718097> <https://research.tib.eu/covid-19/entity/3ewcl1or_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Mishra%2C_S._K.%3B_Tripathi%2C_T.> <https://research.tib.eu/covid-19/entity/Mishra%2C_Sanjay_Kumar%3B_Tripathi%2C_Timir>
?:journal	Acta_Trop Acta_Tropica
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	WHO
?:title	One year update on the COVID-19 pandemic: Where are we now?
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1064688 #947089
?:year	2020

Property

Value

?:abstract

We are living through an unprecedented crisis with the rapid spread of the new coronavirus disease (COVID-19) worldwide within a short time The timely availability of thousands of SARS-CoV-2 genomes has enabled the scientific community to study the origin, structures, and pathogenesis of the virus The pandemic has spurred research publication and resulted in an unprecedented number of therapeutic proposals Because the development of new drugs is time consuming, several strategies, including drug repurposing and repositioning, are being tested to treat patients with COVID-19 Researchers have developed several potential vaccine candidates that have shown promise in phase II and III trials As of 12 November 2020, 164 candidate vaccines are in preclinical evaluation, and 48 vaccines are in clinical evaluation, of which four have cleared phase III trials (Pfizer/BioNTech\'s BNT162b2, Moderna\'s mRNA-1273, University of Oxford & AstraZeneca\'s AZD1222, and Gamaleya\'s Sputnik V vaccine) Despite the acquisition of a vast body of scientific information, treatment depends only on the clinical management of the disease through supportive care At the pandemic\'s 1-year mark, we summarize current information on SARS-CoV-2 origin and biology, and advances in the development of therapeutics The updated information presented here provides a comprehensive report on the scientific progress made in the past year in understanding of SARS-CoV-2 biology and therapeutics
We are living through an unprecedented crisis with the rapid spread of the new coronavirus disease (COVID-19) worldwide within a short time. The timely availability of thousands of SARS-CoV-2 genomes has enabled the scientific community to study the origin, structures, and pathogenesis of the virus. The pandemic has spurred research publication and resulted in an unprecedented number of therapeutic proposals. Because the development of new drugs is time consuming, several strategies, including drug repurposing and repositioning, are being tested to treat patients with COVID-19. Researchers have developed several potential vaccine candidates that have shown promise in phase II and III trials. As of 12 November 2020, 164 candidate vaccines are in preclinical evaluation, and 48 vaccines are in clinical evaluation, of which four have cleared phase III trials (Pfizer/BioNTech\'s BNT162b2, Moderna\'s mRNA-1273, University of Oxford & AstraZeneca\'s AZD1222, and Gamaleya\'s Sputnik V vaccine). Despite the acquisition of a vast body of scientific information, treatment depends only on the clinical management of the disease through supportive care. At the pandemic\'s 1-year mark, we summarize current information on SARS-CoV-2 origin and biology, and advances in the development of therapeutics. The updated information presented here provides a comprehensive report on the scientific progress made in the past year in understanding of SARS-CoV-2 biology and therapeutics.

is ?:annotates of